Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.68 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.65 |
| ▸ | POLB | P06746 | 1/20 | 0.65 |
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.62 |
| ▸ | ACLY | P53396 | 1/20 | 0.57 |
| ▸ | SGMS1 | Q86VZ5 | 1/20 | 0.56 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.56 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.55 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.55 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9813024 | 0.89 | AKR1C3 (0.76) | AKR1C3ALDH1A1POLBSMN1; SMN2ACLY | |
| SCHEMBL4618990 | 0.88 | SFRP1 (0.67) | L3MBTL1AKR1C3ALDH1A1POLBMEN1 | |
| SCHEMBL10047336 | 0.86 | CYP19A1 (0.76) | L3MBTL1ALDH1A1POLBMEN1KMT2A | |
| SCHEMBL30822628 | 0.85 | ALDH1A1 (0.71) | L3MBTL1AKR1C3ALDH1A1MEN1KMT2A | |
| SCHEMBL14751071 | 0.85 | ALDH1A1 (0.71) | L3MBTL1AKR1C3ALDH1A1MEN1KMT2A | |
| SCHEMBL9128548 | 0.84 | ALDH1A1 (0.56) | L3MBTL1AKR1C3ALDH1A1POLBMEN1 | |
| SCHEMBL15619063 | 0.83 | ALDH1A1 (0.88) | AKR1C3ALDH1A1POLBMEN1KMT2A | |
| SCHEMBL9129388 | 0.83 | TBXA2R (0.62) | L3MBTL1AKR1C3ALDH1A1MEN1KMT2A | |
| SCHEMBL17974009 | 0.81 | ALDH1A1 (0.66) | AKR1C3ALDH1A1MEN1KMT2ACYP19A1 | |
| SCHEMBL2595657 | 0.81 | ALDH1A1 (0.66) | L3MBTL1AKR1C3ALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117924125-A | Method for preparing sulfonamide derivative through visible light catalysis without metal participation | 苏州大学 | 2024-04-26 | — | — | CN | disclosed |
| US-20180250308-A1 | NR2B SELECTIVE NMDA-RECEPTOR ANTAGONISTS FOR TREATMENT OF IMMUNE-MEDIATED INFLAMMATORY DISEASES | WESTFALISCHE WILHELMS-UNIVERSITAT MUNSTER (DE) | 2018-09-06 | — | — | US | disclosed |
| EP-3344257-A1 | NR2B SELECTIVE NMDA-RECEPTOR ANTAGONISTS FOR TREATMENT OF IMMUNE-MEDIATED INFLAMMATORY DISEASES | Westfälische Wilhelms-Universität Münster (DE) | 2018-07-11 | — | — | EP | disclosed |
| WO-2017036880-A1 | NR2B SELECTIVE NMDA-RECEPTOR ANTAGONISTS FOR TREATMENT OF IMMUNE-MEDIATED INFLAMMATORY DISEASES | Westfälische Wilhelms-Universität Münster (DE) | 2017-03-09 | — | — | WO | disclosed |
| EP-2246331-A1 | NR2B-selective NMDA-receptor antagonists | Westfälische Wilhelms-Universität Münster (DE) | 2010-11-03 | — | — | EP | disclosed |
| EP-2246331-A1 | NR2B-selective NMDA-receptor antagonists | Westfälische Wilhelms-Universität Münster (DE) | 2010-11-03 | — | — | EP | disclosed |
| WO-2010122134-A1 | NR2B-SELECTIVE NMDA-RECEPTOR ANTAGONISTS | Westfälische Wilhelms Universität Münster (DE) | 2010-10-28 | — | — | WO | disclosed |
| WO-2010122134-A1 | NR2B-SELECTIVE NMDA-RECEPTOR ANTAGONISTS | Westfälische Wilhelms Universität Münster (DE) | 2010-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180250308-A1 | NR2B SELECTIVE NMDA-RECEPTOR ANTAGONISTS FOR TREATMENT OF IMMUNE-MEDIATED INFLAMMATORY DISEASES | GRIN1, GRIN2B, GRIN3B | L3MBTL1 4277/4885AKR1C3 3319/4885ALDH1A1 2771/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.